Abstract
In our earlier reports we have introduced a new method for urea removal in renal failure. This is based on the oral administration of polymeric artificial cells containing nonpathogenic genetically engineered E. coli DH5 cells to renal failure rats. This resulted in the lowering of systemic uremic urea level to normal range without elevation of ammonia. The present article deals with the safety study of this approach. Microscopic study follows changes in microcapsule morphology with time are described. Two parameters, the body weight of the renal failure rats and, the survival for of the renal failure rats receiving microcapsules containing genetically engineered E. coli DH5 cells are discussed in this article. Result shows that there is no significant difference between the weight profile of uremic rats receiving oral therapy and normal control rats. Also the treated group of uremic rats survived longer than the untreated uremic rats.